Background: Inflammatory bowel diseases are costly chronic gastrointestinal diseases. We aimed to determine whether immediate colectomy with ileal pouch-anal anastamosis (IPAA) after diagnosis of severe ulcerative colitis (UC) was cost-effective compared to the standard medical therapy.
The potential efficacy of biologics and some patients' preference to delay surgery has added layers of costly medical therapy to UC patient care. Although the optimal timing of referring patients for a surgical intervention is unclear, a subtotal colectomy with an ileal pouch-anal anastamosis (IPAA) has been shown to have good clinical results and to reduce long-term costs, given appropriate clinical guidelines. 9, 10 Escalating medical therapies, especially biologic therapies, have been shown to be less effective in controlling colitis flares in UC than in Crohn's disease. 11 The aim of our investigation was to perform a costeffectiveness analysis comparing early colectomy with IPAA versus standard medical therapy in a cohort of UC patients. The hypothesis of our study is that patients with severe UC may benefit from improved quality of life and require less health care over a lifetime after an early colectomy with an IPAA instead of escalating through standard medical therapy options. We used deterministic and probabilistic sensitivity analyses to evaluate the robustness of our findings and to identify key parameters influencing model results.
METHODS Decision Analytic Model, Subjects, and Outcomes
We performed a cost-effectiveness analysis following the recommendations of the US Panel on Cost-Effectiveness in Health and Medicine in the development of the model and in the analysis of results, including taking a societal perspective, considering costs and benefits over a lifetime horizon, and discounting at 3% annually. 12 Costs were converted to 2009 US dollars using the US gross domestic product deflator. 13 Base case parameter values and ranges and distributions used in sensitivity analysis are presented in Table 1 . We implemented the model in TreeAge Pro 2009 Suite (TreeAge Software Inc, Williamstown, MA) and Microsoft Excel 2007 (Microsoft Corporation, Redmond, WA).
We constructed a Markov model to simulate a cohort of young adult UC patients from diagnosis at age 21 until death or 100 years of age using 3-month time steps (Fig. 1) . The simulated cohort consists of patients with newly diagnosed severe pancolitis UC confirmed by colonoscopic biopsies. In each cycle, patients in any health state of the model could die at a rate based on average age-specific mortality as estimated by the Centers for Disease Control and Prevention. 14 Patients who survive may continue on their current treatment regimen or they may stop responding to that line of treatment and may move to the next line of therapy. Patients receiving standard medical therapy progress to colectomy with IPAA once all medical management alternatives have been exhausted. On the basis of published data for colorectal cancer (CRC) and dysplasia risk in UC, 55 we assumed that patients received a colectomy if they developed CRC or dysplasia. incremental cost-effectiveness ratio, which is defined as the difference in costs in dollars divided by the difference in effectiveness in quality-adjusted life-years (QALYs) between 2 competing interventions. The model was run probabilistically with 10,000 independent simulations accounting for uncertainty in the individual parameters (probability distributions for the parameters summarized in Table 1 ).
The results of the model are presented 2 ways. First, mean lifetime costs and QALYs for both strategies are reported and their costeffectiveness presented using incremental cost-effectiveness ratios. We calculated confidence intervals (CIs) around the costs and benefits of each strategy and of the incremental cost-effectiveness ratio. Second, decision uncertainty is presented as the probability that each intervention is considered the economically optimal strategy for a given cost-effectiveness threshold.
FIGURE 1.
Simplified schematic of Markov model with health states and transitions. All hypothetical patients entered into the model in severe UC flare during initial hospitalization. Both the standard medical therapy and colectomy with IPAA strategies have associated costs, quality of life estimates measured by utility, and transition state probabilities. (Note: Patients who did not achieve remission during the first cycle on corticosteroids and mesalamine were started on infliximab. Patients on infliximab were allowed 2 relapses before escalating therapy.)
Standard Medical Therapy Strategy
On the basis of the clinical expertise of gastroenterologists at our institution, we modeled a therapeutic strategy that escalates immune-suppression using pharmacotherapies most frequently used in UC. In most gastroenterology practices in the US, escalating medical therapy for UC would consist of a biological agent, such as infliximab, and often a calcineurin inhibitor, such as tacrolimus, at some point along the therapeutic cascade before medical therapy was considered "exhaustive." We also assumed that severe UC patients would be hospitalized during their initial flare, definitively diagnosing them of pan-colitis UC though endoscopic biopsies. During hospitalization, standard medical inpatient care and intravenous methylprednisolone (max dose of 60 mg per day) were used for initial medical therapy. Patients were placed on mesalamine 2 g per day for maintenance once they were able to tolerate oral medicines. Patients who responded to each medical therapy went into a state of remission, defined as Simple Colitis Activity Index (SCAI) score of 2 or less. 15 Patients who had an SCAI score 6 or more were considered to have active colitis. If patients did not achieve remission with methyl-prednisolone or oral prednisone after 2 weeks, they automatically received 3 infliximab infusions at 5 mg per kg per doses as induction therapy over the first 3-month cycle length. Then, they received scheduled maintenance infusions at the same dose every 8 weeks. These patients continued infliximab maintenance therapy until 2 reoccurrences of active colitis. Patients failing infliximab therapy were empirically started on oral tacrolimus at 1.5 mg twice daily.
If patients achieved initial remission on mesalamine and corticosteroids, patients remained on mesalamine until their subsequent UC flare. Patients began AZA 125 mg per day as their maintenance agent for the first 3 months if they failed mesalamine therapy until therapeutic levels of thiopurine metabolites were reached. If patients did not respond or failed AZA maintenance therapy, they then escalated to the standard 3 induction infusions of infliximab at 5 mg per kg per dose over the first 3 month cycle length and then received a scheduled maintenance infusion at the same dose every 8 weeks. As described earlier, 2 UC flares on maintenance infliximab were allowed before patients started oral tacrolimus at 1.5 mg twice daily.
Patients failing tacrolimus therapy after achieving initial remission were considered to have failed medical therapy options at which point they received a colectomy with IPAA. Presence of dysplasia was also clinical grounds for colectomy and IPAA according to UC clinical guidelines. 10
Early Colectomy With IPAA Strategy
Patients in the early colectomy with IPAA arm received a subtotal colectomy and a laparoscopic IPAA after their initial hospitalization. A laparoscopic IPAA was assumed in the model because this surgical approach seems to be increasingly more common; however, the cost ranges in our sensitivity analysis considered the open 2-stage IPAA, which creates an initial diverting loop ileostomy before ostomy take-down and subsequent reanastamosis. We assumed that the long-term quality-of-life differences between the 2 techniques are negligible. After surgery, patients were then considered to be in the "cure" state, but face the risk of developing acute pouchitis. If acute pouchitis continued for more than 3 months despite a standard course of oral metronidazole and ciprofloxacin, patients were considered to have chronic pouchitis. Treatment for chronic pouchitis was the addition of VSL3 to the standard antimicrobial therapy for acute pouchitis. If patients responded to acute or chronic pouchitis therapy, they were transitioned back into the "cure" state.
There are several less common surgical complications (eg, bowel obstructions, pelvic sepsis, pouch leaks, portal vein thrombosis, etc) that were not included in the model. These complications have been reported in literature after IPAA, often via case-series or smaller retrospective studies. From our review of the literature, we did not identify published data that were specific to the patient cohort modeled in our analysis. Although considered, we concluded that inclusion of outdated or nonrobust data to model every possible complication was not feasible and would not enhance the quality of the model. 16 The purpose of our model was to reveal information on an "average" patient with severe UC undergoing either of these 2 different care models.
Health State Transition Probabilities
The model used health state transition probabilities, which estimate rates of moving from one health state to another, published from literature (Table 1) . Pertinent studies were identified by performing a systematic review of literature on MEDLINE, Google Scholar, and Cochrane controlled trials registry. Additional studies were identified by referring to the bibliographies of the selected manuscripts. The base case value was derived from means or medians from the published literature. Weighted averages of means between studies were used when more than one value could be used as the base case value.
Pelvic surgery in female patients of childbearing age may be negatively associated with future fertility. [17] [18] [19] [20] [21] [22] Best efforts were taken in the model to capture the risk of becoming infertile after pelvic surgery for female patients during childbearing age. From our review of literature, there is no definitive population-based study to precisely estimate female patients' true risk of infertility after IPAA, although Waljee et al 53 showed in a meta-analysis that there may be a 3-fold increase in infertility above baseline risk (assumed to affect 10%-15% of couples) after pelvic surgery. Because the true risk in developing infertility after IPAA for female UC patients is not conclusively known, female patients in our model had a baseline 40% probability of infertility after undergoing an IPAA. To capture the entire range of probabilities, our sensitivity analysis considered a probability range of 15% to 50% (Table 1) . Infertile female patients were subject to an appropriate decrement in quality of life (see "Utilities").
Costs
Direct costs of hospitalizations, outpatient visits, procedures, and laboratory costs were estimated using national reimbursements from the Centers for Medicare and Medicaid Services (CMS) for 2009 and average reimbursement rates from all de-identified patient-billing records in 2009 at Stanford University Medical Center (SUMC). Whenever possible, the Office of Statewide Health Planning and Development (OSHPD) tables were used to validate institutional rates to best reflect the national average of costs. Wholesale costs of medical therapies (prednisone, mesalamine, AZA, and infliximab) were estimated by prices from 2 online pharmacies 23 and validated with the drug costs at Lucile Packard Children's Hospital pharmacy.
Utilities
Utilities estimate patient quality of life, ranging from 0 (death) to 1 (perfect health). Patients in severe UC flare and remission had a utility of 0.48 and 0.91, respectively. Muir et al 58 showed that at 6 months after colectomy with IPAA, patients had a similar quality of life as patients in UC remission at a utility of 0.91. A very recent study by Waljee et al, who surveyed a total of 450 patients using Time-Trade-Off utilities, reports that UC patients who had a colectomy had improved quality of life (0.92) than UC patients living with chronic disease (0.86). Although both Muir et al and Waljee et al 24 report similar utilities of 0.91 and 0.92, respectively, we chose to use in our analysis the most conservative utility estimate published in literature of 0.87, reported by Tengs and Wallace. 57 We used this estimate because we wanted our analysis to not underestimate patients who may be inconvenienced by increased hesitancy and frequency of bowel movements and potentially living with incontinence after IPAA. Our sensitivity analysis considered a broad range for this utility variable (0.5 to 0.95) ( Table 1) .
Our analysis also considered that there would be a substantial decrement in women's quality of life if pelvic surgery induced infertility during childbearing age. Hence, infertile female patients after receiving an IPAA were assigned a utility of 0.74, reported by Gift and Owens. 60
Sensitivity Analyses
We performed a deterministic and a probabilistic sensitivity analyses on all health state probabilities, costs, and utilities in the model (Table 1) . One-way deterministic sensitivity analyses were performed over the specified range of values derived from literature and clinical judgment. For probabilistic sensitivity analysis and for calculating the CIs around the base case results, we performed 10,000 independent simulations. Beta distributions were used for probabilities and utilities. Lognormal distributions were used for costs.
RESULTS

Standard Medical Therapy Versus Early Colectomy With IPAA
Our model showed that in the standard medical therapy strategy, 20% of the patients had a colectomy with IPAA after 5 years and more than 40% after 10 years. A summary of the cost-effectiveness of the 2 strategies is shown in Table 2 . The standard medical therapy strategy accrued a total discounted lifetime cost of $236,370 (95% CI: 219,057-255,328). The early colectomy with IPAA strategy accrued a total discounted lifetime cost of $147,763 (137,013-158,904). This represents a savings of $88,607 (73,726-105,865) per person over a lifetime if early colectomy with IPAA were the standard of care instead of escalating medical therapies.
On average, standard medical therapy provided 0.06 more QALYs than the early colectomy with IPAA strategy. Across 10,000 simulations, standard medical therapy provided more QALYs than early colectomy with IPAA 52.0% of the time. The cost-effectiveness planes are shown in Figure 2 .
Deterministic Sensitivity Analyses
We tested the robustness of our findings by varying each of the variables over a wide range of values as listed in Table 1 . This method identifies the key parameters that impact cost-effectiveness of the different strategies and determines whether the dominant strategy could be replaced with the competing strategy if one or more variables changed over the specified range values. Each variable was tested independently to determine whether varying the particular variable significantly alters the incremental cost-effectiveness ratios. Among all the variables tested, only the quality of life after colectomy with IPA caused the incremental cost-effectiveness ratios to fall below the $100,000/QALY threshold. No other variable in the model impacted the cost-effectiveness between the 2 strategies. For discussion purposes, we mention 2 other variables: the annual cost of maintenance infliximab and the one-time cost of colectomy with IPAA. 
Cost of Infliximab and Colectomy With IPAA
The annual cost of maintenance infliximab ($57,894) and the one-time cost of colectomy with IPAA ($68,500) are the 2 most expensive therapeutic options available for the management of UC. For the annual cost of maintenance infliximab, we varied the cost from $14,474 to $115,788. For the one-time cost of colectomy with IPAA, we varied the cost from $34,250 to $137,000. Despite the wide sensitivity ranges for both of these variables, early colectomy with IPAA remained a more cost-effective strategy (incremental costeffectiveness ratios >$500,000 per QALY), providing cost-savings and comparable QALYs.
Quality of Life After Colectomy With IPAA
The utility in the cure state after receiving the colectomy with IPAA was the only sensitive variable in the entire model (Fig. 3 ). In the base case, we assumed a utility of 0.8 for the first 6 months after surgery and 0.87 for 6 months after surgery in the stable cure state. A poor quality of life was necessary for the colectomy with IPAA to be considered cost-ineffective. A utility of 0.72 produced an ICER less than $100,000 per QALY, while 0.55 produced an ICER less than $50,000 per QALY (Fig. 3 ).
Probabilistic Sensitivity Analysis
Probabilistic analysis of the model identified that in 48.0% of scenarios, early colectomy with IPAA decreased costs and increased QALYs (Fig. 4) . Using a willingness to pay threshold of $50,000 per QALY gained, the probability that early colectomy with IPAA is the optimal decision is 99.9%, and using a willingness to pay threshold of $100,000 per QALY gained the probability that early colectomy with IPAA is the optimal decision is 95.6%. At an extreme willingness to pay threshold of $200,000 per QALY gained, standard medical therapy was observed to be the optimal decision in 18.2% of simulations.
DISCUSSION
The aim of our investigation was to perform a costeffectiveness analysis comparing early colectomy with IPAA versus standard medical therapy in a cohort of young adult UC patients with severe disease. Our analysis indicates that exhausting standard medical therapy options may not be cost-effective in the context of severe UC. With the assumptions used in our analysis, which were derived from systematic review of the literature, patients who were referred for surgery after failing most current medical therapies incurred approximately $90,000 in additional costs over a lifetime. Exhaustive medical care, on average, provided a very small increase in quality of life over a lifetime (QALY of 20.78 vs 20.72) compared to early surgery. This small difference in lifetime QALYs on average is emphasized by the probabilistic analysis in which we found that an improvement in QALYs was only observed in just over half of the simulations (52.0%). However, among the simulations in which standard medical therapy cost more and provided more QALYs, it did so with very high incremental cost-effectiveness ratios.
These results were not sensitive to the values of key parameters, when varied over a realistic range: only a very low quality of life 6 months after receiving the colectomy with IPAA could make the standard medical therapy the preferred strategy over the early colectomy with IPAA strategy. Published literature reports that a stable colectomy with IPAA has a utility between 0.87 and 0.92, 24, 57, 58 although we used 0.87 in our model because this was the more clinically conservative estimate, as described in the "Methods" section. Our model shows that a very poor quality of life is required for exhaustive medical therapy in severe UC to be cost-effective. Precisely, for standard medical therapy in severe UC to produce an incremental cost-effectiveness ratio of less than $50,000 per QALY, the utility has to be less than 0.55, which would be comparable to the quality of life having acute or chronic pouchitis with a utility of 0.57. The utility of the cure state has to be less than 0.72 to produce an incremental cost-effectiveness ratio less than $100,000 per QALY.
Our model seeks to simulate actual clinical practice as closely as possible for young patients who often present with medically intractable, severe UC. However, the model makes simplifying assumptions and is only an approximation of real life. Extreme care must be taken to not impose an inflexible protocol on patients who may not fit this clinical picture on the basis of the results of this study in an effort to "save costs." Furthermore, standard medical therapy set forth in our study may not reflect all clinical practices precisely (eg, dual therapies with immunomodulators and biologics, timing of transitioning patients from one therapy to another). We believe that the outcomes of these variations in clinical practice are within the range of scenarios assessed in our sensitivity analysis. Among US clinicians who are experienced in treating UC, the escalating therapy regimen used in our model should be realistic and conceivable.
One limitation of our study is that the majority of our data come from investigations on older adult patients with UC. In our analysis, we chose to simulate a 21-year-old cohort because this younger age represents an age window, where UC patients would more likely present with severe pancolitis. Among adolescent patients, who often present with a more severe UC, it is not clear how the results of this analysis could be extrapolated to a pediatric group, although evidence suggests that there is a high correlation between pediatric and adult UC. 25 Another possible limitation is the generalizability of the cost data. We used single-center reimbursements rates for some costs, which may not represent national averages. However, we attempted to standardize these rates by averaging them with national rates from CMS. We also compared single-center costs with data from OSHPD, which monitors reimbursements to hospitals across the state of California. Furthermore, we showed that all the cost variables (including the most expensive options in infliximab and colectomy with IPAA) were not sensitive-indicating that extremely high and low costs did not affect our results. 3 . Sensitivity analysis on the utility of the cure state after colectomy with IPAA. Incremental cost effectiveness of standard medical therapy compared to early colectomy with IPAA. At a willingness to pay thresholds of $50,000 and $100,000 per QALY, the utilities had to be less than 0.55 and 0.72, respectively, for the standard medical therapy strategy.
Currently, medical therapy options are not standardized and there is little evidence to support clinical decisions regarding medical versus surgical options for severe UC. In our model, the standard medical therapy framework we used is "bare-bones" compared to what may be used in real-life scenarios, which often includes increasing the dose of infliximab to 10 mg/kg/dose, increasing the frequency of infliximab infusions, and changing from infliximab to another biologic agent. These extra layers of medical therapy, especially when biologics are involved, are very expensive, often unproven, and are frequently done in conjunction with systemic steroids, frequent hospitalizations, and overall reductions in the quality of life. Our analysis lays some groundwork for clinicians and health policy makers to consider earlier surgical referral for severe UC.
As mentioned previously, there is evidence to suggest that pelvic surgery in women impacts future fertility. [26] [27] [28] [29] [30] [31] We have tried to incorporate this risk in our model according to available data. Understandably, risk of infertility is the single most important reason to consider delaying colectomy with IPAA for women before or in childbearing age with severe UC. Clinical decisions should take into account the specific clinical circumstances, concerns, and desires of individual patients. Exposure to chronic steroids is detrimental to long-term health with increased risk of stunted growth during childhood, 32-34 cardiovascular disease, 35, 36 osteopenia/osteoporosis, [37] [38] [39] and reduced fertility in both men and women. 40, 41 Furthermore, there is unknown cumulative risk in receiving multiple immunosuppressive medications, including the increased risk of lymphoma, birth defects, and other major organ system dysfunction from chronic immune suppression.
Lastly, some patients and clinicians hold to the notion of waiting for the next medical therapy breakthrough. The decision between escalating medical therapies and referring for early colectomy with or without IPAA should be made on an individually tailored, patient-level basis by balancing the available evidence to support one over the other. The clinician and surgeon need to discuss with each patient to determine which options would enhance the patient's quality of life. The patient may determine that undergoing one immune-suppressive medication after another to achieve a potentially delicate remission is not in his or her best interest when surgical options may produce comparable results. Interestingly, independent from our study, a recent prospective observational study concluded that cohorts with a surgical intervention for UC (Brooke ileostomy or IPAA) were associated with lower health care expenditures but not associated with adverse health outcomes compared to cohorts on medical therapy alone. 9 As previously cited, Waljee et al 24 conducted a thorough analysis using the Time-Trade-Off method to assess patients' quality of life before and after a colectomy. Their investigation concludes that patients who had undergone a colectomy reported a worse utility for their prior chronic UC state than their current postcolectomy state (0.86 vs 0.92, P < 0.001).
In summary, we found through decision analysis that escalating through standard medical therapies in severe UC is not cost-effective. Alternatively, early referral for colectomy with IPAA in these patients may produce comparable quality of life while reducing health care costs. Our model was robust, finding the same result despite wide variations in costs, utilities, and health state probabilities. Only an extremely low quality of life after receiving a colectomy with IPAA could maintain the standard medical therapy strategy as the optimal management strategy in severe UC.
